Cardima receives Shonin approval from the Japanese MHLW to market PATHFINDER catheters

Cardima, Inc. (OTC/BB: CADM), a medical device company focused on the diagnosis and treatment of atrial fibrillation (AF), has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to re-enter the Japanese market with its family of guidewire-based, multi-electrode PATHFINDER® diagnostic mapping catheters. Cardima’s PATHFINDER catheters, which are designed for accessing and mapping the vasculature of the heart wall to facilitate treatment of arrhythmias, will be imported into Japan through an exclusive distribution agreement with medical device distributor Robert Reid Inc., an import license holder, and marketed through Japan Lifeline Co. Ltd., an exclusive distributor of Robert Reid Inc.

“We increased our PATHFINDER inventory in anticipation of this approval and have already begun shipping products to Japan. PATHFINDER sales in Japan have the potential to provide Cardima with large revenue generation opportunities.”

“We are delighted to resume sales of our PATHFINDER catheters in Japan through Japan Lifeline, a well-established cardiac device distributor with an extensive marketing network within the electrophysiology and interventional cardiology communities. We thank Robert Reid for partnering with us and managing the Shonin process,” said Robert Cheney, Cardima’s CEO. “We increased our PATHFINDER inventory in anticipation of this approval and have already begun shipping products to Japan. PATHFINDER sales in Japan have the potential to provide Cardima with large revenue generation opportunities.”

Mr. Hideo Shitoto, President of Robert Reid Inc., stated, “The PATHFINDER’s low profile, small size, flexibility and multi-electrode design allow for entry into the most difficult and remote regions of the coronary vasculature. We believe these competitive features will be well received by the Japanese medical community. We look forward to reintroducing this product line in Japan and we hope to expand our relationship with Cardima to include additional products in the future.”

The PATHFINDER catheter is also approved for marketing in the U.S., Europe, Canada and Thailand.

http://www.cardima.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals rare genetic variants significantly increase atrial fibrillation risk